Grouping Products and Equipment for a Worst-Case Cleaning Validation Study

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, August 2021 Issue
Volume 45
Issue 8
Pages: 44–51

A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.

KADMY - STOCK.ADOBE.COM

KADMY - STOCK.ADOBE.COM

Peer-Reviewed

Submitted: December 1, 2020
Accepted: February 5, 2021

Abstract

Cleaning validation requires a significant effort to design a strategic and effective program that is defendable with regulatory agencies. Of primary concern is what to validate. A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.

Click here to read Grouping Products and Equipment for a Worst-Case Cleaning Validation Study (PDF).

About the author

Richard Forsyth is a Principal Consultant with Forsyth Pharmaceutical Consulting.

Article Details

Pharmaceutical Technology
Vol. 45, No. 8
August 2021
Pages: 44–51

Citation

When referring to this article, please cite it as R. Forsyth, "Grouping Products and Equipment for a Worst-Case Cleaning Validation Study," Pharmaceutical Technology 45 (8) 2021.

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development